Les Funtleyder News
-
One worked for Lazard Ltd., the other for Merrill Lynch & Co. One studied industrial engineering at the Universidad Iberoamericana in Mexico, the other politics at Princeton University.
-
Prudential Financial Inc. and MetLife Inc. are moving onto Aflac Inc.’s turf selling protection against diseases and accidents as the largest insurers seek to add business tied to President Barack Obama’s health overhaul and win valuations like their smaller rival.
-
Eli Lilly & Co. , already facing competition next year for its top-selling drug, lost a court bid over patent protection on its cancer medicine Gemzar , which could lead to generic products as early as November.
-
Puma Biotechnology Inc.’s surging valuation is stoking optimism its chief executive officer will succeed in selling his second straight drug developer to a major pharmaceutical company.
-
Theravance Inc.’s projected U.S. approval for its respiratory drugs is fueling speculation of an almost threefold revenue surge and a takeover bid from partner GlaxoSmithKline Plc.
-
Les Funtleyder, president of Poliwogg's Investment Advisory division, Bloomberg senior economist Joe Brusuelas, and Ben Willis, managing director at Albert Fried & Co. LLC., discuss the economic impact of President Obama's Affordable Care Act. Funtleyder, Brusuelas and Willis talk with Bloomberg's Courtney Donohoe on Bloomberg Radio's "Taking Stock."
-
Berkshire Hathaway Inc. has been buying about 1 million shares a month of dialysis-center operator DaVita HealthCare Partners Inc., making the holding among the dozen largest at Warren Buffett’s company.
-
John Tricas said he heard opportunity knocking and learned networking software two decades ago, when it was the “next big thing.” Now he senses a similar opening as the health-care overhaul law takes effect.
-
Senator Charles E. Grassley said he will investigate how an investor services firm specializing in so-called political intelligence got early word of a Medicare- rate decision that led to a surge in health insurer stocks.
-
Pfizer Inc. agreed to pay about $330 million to resolve claims that its Prempro menopause drug caused breast cancer, in the first large-scale settlements in eight years of litigation, two people familiar with the accords said.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page